Background
Hydatidiform mole can be subdivided into complete and partial mole based on genetic and histopathological features. Complete moles are diploid and androgenetic in origin, with no evidence of fetal tissue. Complete moles usually arise as a consequence of duplication of the haploid sperm following fertilisation of an 'empty' ovum. Some complete moles arise after dispermic fertilisation of an 'empty' ovum. Partial moles are triploid in origin with two sets of paternal haploid genes and one set of maternal haploid genes.They occur, in almost all cases, following dispermic fertilisation of an ovum.There is usually evidence of a fetus or fetal red blood cells.
The widespread use of ultrasound has led to earlier diagnosis of pregnancy and has changed the pattern of molar pregnancy. The majority of women present with symptoms of early pregnancy failure while presentation with hyperemesis, early severe pre-eclampsia and hyperthyroidism is very rare.
In the UK, there exists an effective registration and treatment programme. The programme has achieved impressive results, with high cure (98-100%) and low (5-8%) chemotherapy rates. 
Diagnosis of gestational trophoblastic neoplasia
Early complete molar pregnancies are commonly associated with the ultrasound diagnosis of delayed miscarriage or anembryonic pregnancy. Complete moles may be associated with suggestive ultrasonographic changes in the placenta. However, ultrasound has limited value in detecting partial molar pregnancies. In twin pregnancies with a viable fetus and a molar pregnancy, the pregnancy should be allowed to proceed.
The increasing use of ultrasound in early pregnancy has probably led to the earlier diagnosis of molar pregnancy. However, the majority of histologically proven complete moles are associated with an ultrasound diagnosis of delayed miscarriage or anembryonic pregnancy. 3 The ultrasound features of a complete mole are reliable but the ultrasound diagnosis of a partial molar pregnancy is more complex.The finding of multiple soft markers, including both cystic spaces in the placenta and a ratio of transverse to anterior-posterior dimension of the gestation sac of greater than 1.5 is required for the reliable diagnosis of a partial molar pregnancy. 4 Estimation of human chorionic gonadotrophin (hCG) levels may be of value in diagnosing molar pregnancies. When there is diagnostic doubt about the possibility of a combined molar pregnancy with a viable fetus then ultrasound examination should be repeated before intervention. In the situation of a twin pregnancy, where there is one viable fetus and the other pregnancy is molar, the pregnancy should be allowed to proceed if the mother wishes, following appropriate counselling.The probability of achieving a viable baby is 40% and there is a risk of complications such as pulmonary embolism and pre-eclampsia. There is no increased risk of developing persistent GTN after such a twin pregnancy and outcome after chemotherapy is unaffected. 5 
Evacuation of molar pregnancies
Surgical evacuation of molar pregnancies is advisable. Routine repeat evacuation after the diagnosis of a molar pregnancy is not warranted.
Suction curettage is the method of choice of evacuation for complete molar pregnancies. Because of the lack of fetal parts a suction catheter, up to a maximum of 12 mm, is usually sufficient to evacuate all complete molar pregnancies. Medical termination of complete molar pregnancies, including cervical preparation prior to suction evacuation, should be avoided where possible. 6, 7 There is theoretical concern over the routine use of potent oxytocic agents because of the potential to embolise and disseminate trophoblastic tissue through the venous system. This is known to occur in normal pregnancy, especially when uterine activity is increased, e.g. with accidental haemorrhage. 8 The contraction of the myometrium may force tissue into the venous spaces at the site of the placental bed.The dissemination of this tissue may lead to the profound deterioration in the woman, with embolic and metastatic disease occurring in the lung.While it is recognised that significant haemorrhage may occur as a consequence of evacuating a large uterine
cavity, it is recommended, where possible, that oxytocic infusions are only commenced once evacuation has been completed. If the woman is experiencing significant haemorrhage prior to evacuation and some degree of control is required then use of these agents will be necessary according to the clinical condition. Oxytocic infusions have been in common use for this purpose. It is suggested that prostaglandin analogues should be reserved for cases where oxytocin is ineffective. Because evacuation of a large molar pregnancy is a rare event, advice and help from an experienced colleague should be sought where appropriate. In partial molar pregnancies where the size of the fetal parts deters the use of suction curettage, medical termination can be used. These women may be at an increased risk of requiring treatment for persistent trophoblastic neoplasia, although the proportion of women with partial molar pregnancies needing chemotherapy is low (0.5%). 9 Data from the management of molar pregnancies with mifepristone are limited. 7 Evacuation of complete molar pregnancies with this agent should be avoided at present since it increases the sensitivity of the uterus to prostaglandins.
Histological examination of products of conception
All products of conception obtained after evacuation (medical or surgical) should undergo histological examination. Products of conception from therapeutic terminations of pregnancy should be examined if there is no evidence of fetal tissue.
In view of the difficulty in making a diagnosis of a molar pregnancy before evacuation, the histological assessment of material obtained from the medical or surgical management of incomplete miscarriage is recommended in order to exclude trophoblastic neoplasia. 10 Ploidy status may help in distinguishing partial from complete moles. Because persistent trophoblastic neoplasia may develop after any pregnancy it is recommended that all products of conception obtained after repeat evacuation should undergo histological examination. There is no clinical indication for the routine use of a second uterine evacuation in the management of molar pregnancies. 7 Uterine evacuation may be recommended, in selected cases, by the screening centre as part of the management of persistent trophoblastic neoplasia.
Persistent GTN after a nonmolar pregnancy
Women with persistent abnormal vaginal bleeding after a nonmolar pregnancy should undergo a pregnancy test to exclude persistent GTN. Persistent GTN should be considered in any woman developing acute respiratory or neurological symptoms after any pregnancy.
Persistent GTN can occur after nonmolar pregnancies. Vaginal bleeding is a common presenting symptom but symptoms from metastatic disease, such as dyspnoea or abnormal neurology, can occur. The prognosis for women with GTN after nonmolar pregnancies may be worse (21% mortality after a live birth, 6% after a nonmolar miscarriage) and in part due to the delay in diagnosis (0.5-58.0 months). 10 Urgent referral of such cases should occur. 
Treatment of persistent GTN
Women with persistent GTN should be treated at a specialist centre with appropriate chemotherapy.
The need for chemotherapy following a complete mole is 15% and 0.5 % after a partial mole. 9 Persistent GTN requiring chemotherapy after other pregnancies is rare precluding accurate assessment.
Women with evidence of persistent GTN should undergo assessment of their disease followed by chemotherapy. Disease risk is scored according to the FIGO staging for GTN. 12 Women scoring six or less (low risk) receive intramuscular methotrexate on alternate days, followed by six rest days, with each course consisting of four injections. 13 Women who develop resistance to methotrexate are treated with a combination of intravenous dactinomycin and etoposide.Women scoring seven or more (high risk) receive combination chemotherapy.At the Charing Cross Hospital, London, the treatment is intravenous etoposide, methotrexate, dactinomycin for two days followed by vincristine and cyclophosphamide (EMA-CO) one week later.The course is then repeated after six days. At Weston Park Hospital, Sheffield, the treatment is intravenous methotrexate followed by dactinomycin and etoposide one week later. The course is then repeated after one week. 2 Treatment is continued, in all cases, until the hCG level has returned to normal and then for a further six consecutive weeks.
Placental site trophoblastic tumour
Advice on the management of these rare tumours should be sought from the appropriate registration centre.
Placental site trophoblastic tumour is now recognised as a variant of gestational trophoblastic neoplasia. Surgery and multi-agent chemotherapy play major roles in the clinical management of this tumour. 
Future pregnancy
Women should be advised not to conceive until the hCG level has been normal for six months.
Women should be advised not to conceive until their hCG levels have been normal for six months. The risk of a further molar pregnancy is low (1/55) and more than 98% of women who become pregnant following a molar pregnancy will not have a further mole or be at increased risk of obstetric complications. If a further molar pregnancy does occur, in 68-80% of cases it will be of the same histological type. 16 After the conclusion of any further pregnancy, at any gestation, further urine or blood samples for hCG estimation are requested to exclude disease recurrence. Women who undergo chemotherapy are advised not to conceive for one year after completion of treatment.
Contraception and hormone replacement therapy
The combined oral contraceptive pill and hormone replacement therapy are safe to use after hCG levels have reverted to normal.
The combined oral contraceptive pill, if taken while hCG levels are raised, may increase the need for treatment. However, it can be used safely after the hCG levels have returned to normal. 9 Other forms of hormonal contraception do not appear to be linked to an increased need for treatment. The small potential risk of using emergency hormonal contraception, in women with raised hCG levels, is outweighed by the potential risk of pregnancy to the woman. Hormone replacement therapy may be used safely once hCG levels have returned to normal.
Auditable outcomes
The proportion of women with GTN registered with the relevant screening centre.This would include:
• complete hydatidiform mole 
